-
-
-
-
-
-
-
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiova
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
-
-
15,464 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

